Please email [email protected] if the presentation you are looking for is not available.
The Role of Serum Biomarkers in the Management of MS
Chair: Mark S. Freedman, MSc MD FRCPC (University of Ottawa)
This session introduces and builds on your understanding of neurofilament light chain use in Multiple Sclerosis (MS). The session focus will be on understanding the rationale and reviewing the evidence for using fluid biomarkers, specifically neurofilament light chain (NfL) measurement, to inform on MS management. The background lecture will set the scene and provide some rationale, followed by a discussion regarding the evidence that NfL measurement at baseline predicts prognosis affording decisions regarding escalation vs. induction treatment approaches. Participants will learn about confounding conditions to consider when interpreting the measurement and examine how individual patient measurement can aid in monitoring response to treatment. In the end, we hope to convey enough information to participants that they feel as comfortable in utilizing NfL measurement as they would MRI, and will illustrate its use with a few case discussions. Level of Information: Intermediate
Speaker: Gauruv Bose, MD (Univ of Ottawa and Ottawa Hospital Research Institute)
Speaker: Ronald A Booth, PhD, FCACB (University of Ottawa)
Speaker: Peter Calabresi, MD (Johns Hopkins University)
Speaker: Simon Thebault, MBBCh, MSc, MRCP (University of Ottawa)
Speaker: Sharmilee Gnanapavan, MD, PhD (Queen Mary University of London)
Speaker: Mark S. Freedman, MSc, MD, FRCPC (University of Ottawa)
CATEGORY:
Science of MS | Symposium
LEVEL:
Intermediate
CREDIT TYPES AND UNITS:
AAPA: 2.75
ACPE: 2.75
CME: 2.75
NCPD: 2.75